CANCER HAS NO BORDERS
NEITHER DO WE
Cancer has no borders. Neither do we.

Our Commitment to Patients

We strive every day to create high-quality, innovative medicines that are more accessible and affordable to more people. We want to ensure patients can access them: it’s not enough for innovative drugs to simply exist.

We work with cancer communities in the U.S. and around the world to learn from and provide support to patients, caregivers, and families to raise awareness and improve lives.

- We communicate honestly, transparently, and accurately.
- We listen with empathy to learn from patients/caregivers and connect with them.
- We respect the healthcare provider/patient relationship.
- We empower patients through education and resources to manage their disease.
- We respect diversity and promote inclusion among all people impacted by cancer.
- We support initiatives and programs that help patients live fuller, more engaged lives.
- We provide opportunities for our employees to engage with cancer communities.

The BeiGene Story

A global biotechnology innovator focused on improving treatment outcomes and patient access.

BeiGene is a global biotechnology company co-founded in 2010 by John Oyler, an American entrepreneur, and Dr. Xiaodong Wang, world-renowned biochemist and youngest ever U.S. Academy of Science member, to deliver cancer medicines more broadly and improve the lives of patients worldwide.

Our founders united to benefit patients with cancer – wherever they live - by building a unique operating model, founded on the belief that innovative, impactful and high-quality medicines can be made faster and more affordable around the world.

Today, we are more than 8,500 colleagues across five continents. We have built sustainable competitive advantages including predominantly fully integrated global clinical development, science-based commercial teams in China, the U.S., and Europe, a robust research pipeline, and state-of-the-art internal manufacturing capabilities.

Our internally-developed BTK inhibitor, zanubrutinib, is approved in more than 50 countries and regions around the world.

Our mission is to build the first next-generation biotechnology company – one that expands the highest quality therapies to more people around the world, through courage, persistent innovation, and challenging the status quo.

Our passion is partnership.
Our commitment to patients is resolute.

We strive every day to create high-quality, innovative medicines that are more accessible and affordable to more people. We want to ensure patients can access them: it’s not enough for innovative drugs to simply exist.

We work with cancer communities in the U.S. and around the world to learn from and provide support to patients, caregivers, and families to raise awareness and improve lives.

- We communicate honestly, transparently, and accurately.
- We listen with empathy to learn from patients/caregivers and connect with them.
- We respect the healthcare provider/patient relationship.
- We empower patients through education and resources to manage their disease.
- We respect diversity and promote inclusion among all people impacted by cancer.
- We support initiatives and programs that help patients live fuller, more engaged lives.
- We provide opportunities for our employees to engage with cancer communities.

Commitment to Patients

Cancer has no borders. Neither do we.

Our mission is to build the first next-generation biotechnology company – one that expands the highest quality therapies to more people around the world, through courage, persistent innovation, and challenging the status quo.

Our passion is partnership.
Our commitment to patients is resolute.

We strive every day to create high-quality, innovative medicines that are more accessible and affordable to more people. We want to ensure patients can access them: it’s not enough for innovative drugs to simply exist.

We work with cancer communities in the U.S. and around the world to learn from and provide support to patients, caregivers, and families to raise awareness and improve lives.

- We communicate honestly, transparently, and accurately.
- We listen with empathy to learn from patients/caregivers and connect with them.
- We respect the healthcare provider/patient relationship.
- We empower patients through education and resources to manage their disease.
- We respect diversity and promote inclusion among all people impacted by cancer.
- We support initiatives and programs that help patients live fuller, more engaged lives.
- We provide opportunities for our employees to engage with cancer communities.

Cancer has no borders. Neither do we.
Cancer has no borders. Neither do we.

We are advancing an innovative, high-value product candidate portfolio in the service of patients worldwide, as we are committed to improving global access and affordability.

Our world-class research and development engine has:

- One of the largest oncology research teams and portfolios
- 14 internally-discovered molecules to the clinic in the first 10 years
- 3 internally discovered approved medicines
- 40 molecules at commercial or clinical stage
- 50+ preclinical programs ongoing, 50% of which are potentially first-in-class
- 30+ Phase 3 or potentially registration-enabling trials

Our Clinical Pipeline from Internal Discovery

We are passionate about applying cutting-edge science to the development of life-changing therapies.

BeiGene’s current pipeline, including early stage clinical development assets, is available at www.BeiGene.com.

Late-Stage Clinical Development

- Zanubrutinib (BTK)
  - Second generation small molecule inhibitor of Bruton’s tyrosine kinase
  - Currently being investigated as a monotherapy and in combination with other therapies in multiple hematologic malignancies

- Toliretlumab (PD-1)
  - Humanized IgG4 anti-PD-1 monoclonal antibody
  - Currently being investigated as a monotherapy and in combination with other therapies in multiple solid tumors and hematologic malignancies

- Pamiparib (PARP)
  - Small molecule inhibitor of PARP1 and PARP2
  - Currently being investigated as a monotherapy and in combination with other therapies in multiple solid tumors

- Orpimitilumab (TIGIT)
  - Investigational TIGIT monoclonal antibody
  - Currently being investigated in combination with toleranumab in solid tumors

Early-Stage Clinical Development

- BGB-A445 (OX40)
  - Investigational OX40 agonist antibody
  - Currently being investigated as a monotherapy and in combination with toleranumab in solid tumors

- BGB-A425 (TIM-3)
  - Investigational humanized IgG1-variant monoclonal antibody against TIM-3
  - Currently being investigated in combination with toleranumab in solid tumors

- BGB-1437 (BCL-2)
  - Investigational small molecule Bcl-2 inhibitor
  - Currently being investigated as a monotherapy and in combination with toleranumab in solid tumors

- BGB-11417 (BCL-2)
  - Investigational small molecule inhibitor of the RAF protein
  - Currently being investigated as a monotherapy and in combination with other therapies in solid tumors

- BGB-10188 (PI3Kδ)
  - Investigational small molecule inhibitor of the PI3Kδ kinase
  - Currently being investigated as a monotherapy and in combination with other therapies in solid tumors

- Lifirafenib (BRAF Dimer)
  - Investigational small molecule inhibitor of the BRAF protein
  - Currently being investigated as a monotherapy and in combination with other therapies in solid tumors

- BGB-23339 (TYK2)
  - Investigational tyrosine kinase 2 (TYK2) inhibitor
  - Currently being investigated as a monotherapy in inflammation and immunity

Safety and efficacy have not been established for investigational products and uses.
Cancer has no borders. Neither do we.

We are committed to collaborating with academia, biotech and pharmaceutical companies around the world to jointly discover and develop innovative products that will bring meaningful treatments to patients.

Partner of Choice

Global strategic oncology collaborations to expand access to important oncology medicines for patients around the globe.

Amgen Collaboration:
- BeiGene is commercializing three Amgen oncology products in China — XGEVA® (denosumab), KYPROLIS® (carfilzomib) and BLINCYTO® (blinatumomab).
- Amgen invested $2.8B for a 20.5% stake in BeiGene.

Novartis Collaborations:
- Novartis to co-develop and commercialize BeiGene’s Anti-PD-1 Antibody Tislelizumab in North America, Japan, EU, and 8 other European countries.
- Novartis has an option for BeiGene and Novartis to collaborate on the development, manufacturing and commercialization of BeiGene’s investigational TIGIT Inhibitor Ociperlimab in North America, Japan, EU and 6 other European countries.
- BeiGene to market and promote five Novartis approved and nationally reimbursed oncology products, including TAFINLAR® (dabrafenib), MEKINIST® (trametinib), VOTRIENT® (pazopanib), AFINITOR® (everolimus), ZYKADIA® (ceritinib), in designated regions of China referred to as Broad Markets.

Additional Collaborations

Amgen Collaboration:
- Amgen and BeiGene are developing and commercializing BeiGene’s Anti-PD-1 Antibody Tislelizumab in China, Japan, EU, and 8 other European countries.
- Amgen has agreed to pay BeiGene a $2.8 billion milestone-based payment if the companies reach certain regulatory milestones.
- BeiGene and Amgen will share profits from the sale of Tislelizumab in China, Japan, EU, and 8 other European countries.

Novartis Collaboration:
- Novartis has an option for BeiGene and Novartis to collaborate on the development, manufacturing and commercialization of BeiGene’s investigational TIGIT Inhibitor Ociperlimab in North America, Japan, EU and 6 other European countries.
- BeiGene to market and promote five Novartis approved and nationally reimbursed oncology products, including TAFINLAR® (dabrafenib), MEKINIST® (trametinib), VOTRIENT® (pazopanib), AFINITOR® (everolimus), ZYKADIA® (ceritinib), in designated regions of China referred to as Broad Markets.

Change Is The Cure

At BeiGene, we believe that Change Is The Cure. Our ambition is to be a leading corporate citizen, acting with courage, creativity, and discipline to ensure we are meeting the diverse needs of our stakeholders – from patients and colleagues to investors and communities, as well as the environment.

We lead change by:
- Making life-saving medicines accessible to more patients around the world.
- Challenging the status quo and pushing the boundaries to make the impossible possible.
- Removing systemic injustices and inequities.
- Creating boundless opportunities for people to thrive.
- Having the transformative ability to shift paradigms.

At BeiGene, we formalized its Environmental, Social, and Governance (ESG) function and defined the company’s new global ESG strategy and framework, Change Is The Cure, in 2021.
Cancer has no borders. Neither do we.